Search research articles
Contact Us
Filters
Showing results (1-10 of 59) with videos related to
Page
of 6
Sort By:
Annals of Hematology
|
June 26, 2023
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group
Julia von Tresckow, Nikola Heyl, Sandra Robrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 20, 2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax
Moritz Fürstenau, Jonathan Weiss, Adam Giza, et al.
Haematologica
|
March 18, 2021
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients
Johannes Bloehdorn, Julia Krzykalla, Karlheinz Holzmann, et al.
Haematologica
|
November 2, 2020
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)
Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, et al.
Leukemia
|
May 6, 2022
The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia
Lisa Rusyn, Sebastian Reinartz, Anastasia Nikiforov, et al.
British Journal of Haematology
|
November 22, 2018
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia
Othman Al-Sawaf, Jasmin Bahlo, Sandra Robrecht, et al.
European Journal of Haematology
|
April 14, 2026
Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry
Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, et al.
Leukemia & Lymphoma
|
September 19, 2022
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older
Florian Simon, Adam Giza, Sandra Robrecht, et al.
Leukemia & Lymphoma
|
September 21, 2018
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance
Natali Pflug, Paula Cramer, Sandra Robrecht, et al.
Blood
|
June 4, 2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations
Paula Cramer, Eugen Tausch, Julia von Tresckow, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 59) with videos related to
Sort By:
Page
of 6
Annals of Hematology
|
June 26, 2023
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group
Julia von Tresckow, Nikola Heyl, Sandra Robrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 20, 2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax
Moritz Fürstenau, Jonathan Weiss, Adam Giza, et al.
Haematologica
|
March 18, 2021
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients
Johannes Bloehdorn, Julia Krzykalla, Karlheinz Holzmann, et al.
Haematologica
|
November 2, 2020
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)
Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, et al.
Leukemia
|
May 6, 2022
The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia
Lisa Rusyn, Sebastian Reinartz, Anastasia Nikiforov, et al.
British Journal of Haematology
|
November 22, 2018
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia
Othman Al-Sawaf, Jasmin Bahlo, Sandra Robrecht, et al.
European Journal of Haematology
|
April 14, 2026
Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry
Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, et al.
Leukemia & Lymphoma
|
September 19, 2022
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older
Florian Simon, Adam Giza, Sandra Robrecht, et al.
Leukemia & Lymphoma
|
September 21, 2018
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance
Natali Pflug, Paula Cramer, Sandra Robrecht, et al.
Blood
|
June 4, 2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations
Paula Cramer, Eugen Tausch, Julia von Tresckow, et al.
Page
of 6